Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST266 for Persistent Corneal Epithelial Defects
NCT05066698Phase 2Terminated
- Sponsor
- Noveome Biotherapeutics
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Cytokines & Interferons, Hormones & Growth Factors
- Countries
- 1
01
Overview
A Phase 2 trial of ST266 in persistent corneal epithelial defect (PED), sponsored by Noveome Biotherapeutics. Started Apr 2022; status: terminated.
02
Drugs
ST266
03
Conditions
persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT05066698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05066698.